- Home
- RHLDV vs AVIR Comparison
RHLDV vs AVIR Comparison
Compare RHLDV & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHLDV
- AVIR
- Stock Information
- Founded
- RHLDV N/A
- AVIR 2012
- Country
- RHLDV United States
- AVIR United States
- Employees
- RHLDV N/A
- AVIR N/A
- Industry
- RHLDV Finance: Consumer Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- RHLDV Finance
- AVIR Health Care
- Exchange
- RHLDV Nasdaq
- AVIR Nasdaq
- Market Cap
- RHLDV 220.6M
- AVIR 251.7M
- IPO Year
- RHLDV N/A
- AVIR 2020
- Fundamental
- Price
- RHLDV $35.77
- AVIR $3.13
- Analyst Decision
- RHLDV
- AVIR Hold
- Analyst Count
- RHLDV 0
- AVIR 1
- Target Price
- RHLDV N/A
- AVIR $6.88
- AVG Volume (30 Days)
- RHLDV N/A
- AVIR 319.6K
- Earning Date
- RHLDV N/A
- AVIR 03-03-2025
- Dividend Yield
- RHLDV N/A
- AVIR N/A
- EPS Growth
- RHLDV N/A
- AVIR N/A
- EPS
- RHLDV N/A
- AVIR N/A
- Revenue
- RHLDV N/A
- AVIR N/A
- Revenue This Year
- RHLDV N/A
- AVIR N/A
- Revenue Next Year
- RHLDV N/A
- AVIR N/A
- P/E Ratio
- RHLDV N/A
- AVIR N/A
- Revenue Growth
- RHLDV N/A
- AVIR N/A
- 52 Week Low
- RHLDV N/A
- AVIR $2.75
- 52 Week High
- RHLDV N/A
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- RHLDV N/A
- AVIR 53.26
- Support Level
- RHLDV N/A
- AVIR $3.05
- Resistance Level
- RHLDV N/A
- AVIR $3.22
- Average True Range (ATR)
- RHLDV 0.00
- AVIR 0.13
- MACD
- RHLDV 0.00
- AVIR 0.02
- Stochastic Oscillator
- RHLDV 0.00
- AVIR 74.19
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).